Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Antiepileptics. Barbiturates

Updated · Methodology

Mechanism

Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Phenobarbital is a potent inducer of drug-metabolising enzymes (cytochrome P450 enzymes and UDP-glycosyltransferases) and can speed up the metabolism of many drugs and reduce their efficacy. According to the Spanish phenobarbital SmPC, the efficacy of oral anticoagulants decreases (phenobarbital SmPC, AEMPS). The US phenobarbital label names acenocoumarol explicitly. Barbiturates can induce liver enzymes, so oral anticoagulants such as acenocoumarol, warfarin, dicoumarol and phenprocoumon are metabolised faster and their anticoagulant response decreases (phenobarbital prescribing information, US Food and Drug Administration, FDA). The acenocoumarol SmPC also lists barbiturates, for example phenobarbital, among drugs that can reduce its effect (acenocoumarol SmPC, AEMPS).

Symptoms

The anticoagulant effect of acenocoumarol decreases (phenobarbital summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens. After phenobarbital is stopped, the effect of acenocoumarol can increase again, especially if its dose was raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).

Management

The combination is not contraindicated but needs close coagulation monitoring. The Spanish phenobarbital summary of product characteristics (SmPC) places oral anticoagulants among combinations that call for caution, clinical monitoring and/or dose adjustment. During combined treatment, check the prothrombin time and the international normalised ratio (INR) frequently. Adjust the anticoagulant dose throughout phenobarbital treatment and for 8 days after it is stopped (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPC lists barbiturates such as phenobarbital among drugs that need close and frequent coagulation checks, for example twice a week, both when they are added and when they are stopped (acenocoumarol SmPC, AEMPS). According to the US phenobarbital label, patients stabilised on anticoagulant therapy may need dose adjustment when a barbiturate is added or withdrawn (phenobarbital prescribing information, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Phenobarbital